[Plaunotol].
Ito
Shigeji
S
Division of Internal Medicine, Tannan Regional Medical Center.
Azuma
Takeshi
T
Yamazaki
Yukinao
Y
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000658:Amoxicillin / Q000627:therapeutic use; D000897:Anti-Ulcer Agents / Q000494:pharmacology / Q000627:therapeutic use; D017291:Clarithromycin / Q000627:therapeutic use; D004224:Diterpenes; D024881:Drug Resistance, Bacterial; D004359:Drug Therapy, Combination; D005233:Fatty Alcohols / Q000494:pharmacology / Q000627:therapeutic use; D016481:Helicobacter Infections / Q000150:complications / Q000188:drug therapy*; D016480:Helicobacter pylori / Q000187:drug effects; D006801:Humans; D064747:Lansoprazole; D018375:Neutrophil Activation / Q000187:drug effects; D009853:Omeprazole / Q000031:analogs & derivatives* / Q000627:therapeutic use; D010437:Peptic Ulcer / Q000188:drug therapy / Q000209:etiology; D011379:Prognosis
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents; D004224:Diterpenes; D005233:Fatty Alcohols; D064747:Lansoprazole; D000658:Amoxicillin; D017291:Clarithromycin; D009853:Omeprazole; C047686:plaunotol